Trust Signals
Key Takeaways
- The glow protocol typically stacks GHK-Cu, Epithalon, and BPC-157; no single published RCT has tested the combination blend, so dosing is extrapolated from each peptide's individual literature.
- GHK-Cu has human cosmetic-injection studies at doses of 0.1 to 1 mg per session; Epithalon has small human pilot data at 5 to 10 mg per day; BPC-157 has rodent data at roughly 10 micrograms per kilogram body weight but no approved human dose.
- Subcutaneous injection is the only route with meaningful bioavailability for these peptides; oral delivery is nearly fully blocked by GI proteolysis.
- A 5 mg vial reconstituted with 2.5 mL bacteriostatic water yields 2 mg/mL; drawing 0.1 mL on a 100-unit insulin syringe delivers 0.2 mg.
- HPLC purity above 98% plus mass spectrometry molecular weight confirmation are the minimum COA requirements worth trusting; purity alone does not confirm correct sequence.
What Is the Standard Glow Peptide Dosage?
Table of Contents
- What peptides are in the glow protocol?
- Evidence ledger: graded claims
- Glow peptide dosage chart
- How does the glow blend work, with numbers?
- What most dosage pages get wrong
- Reconstitution and injection math
- Honest head-to-head: glow protocol vs. alternatives
- How to read a glow peptide COA
- Cycle length and timing
- FAQ
- Sources
What Peptides Are in the Glow Protocol?
The "glow protocol" is a branded compounding term used in the aesthetic and longevity peptide space, not an FDA-approved product name. Different compounding pharmacies and research supply vendors formulate it differently. The most common stack referenced under this name includes:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- GHK-Cu (copper tripeptide-1): A naturally occurring copper-binding peptide with documented roles in collagen synthesis signaling, antioxidant gene expression, and wound healing.
- Epithalon (Epitalon): A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland extract Epithalamin, studied for telomerase activation and immune modulation.
- BPC-157 (Body Protection Compound 157): A 15-amino-acid stable gastric pentadecapeptide fragment studied for tissue repair, gut integrity, and angiogenesis in animal models.
Some blends add Thymosin Beta-4 fragment (TB-500), Thymalin, or Cerebrolysin components. Verify the label of any specific product before applying the doses in this guide.
Evidence Ledger: Graded Claims
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| GHK-Cu increases collagen and glycosaminoglycan synthesis in skin | In-vitro + small human cosmetic studies (Pickart et al.) | Positive | Moderate |
| GHK-Cu upregulates antioxidant genes (SOD, catalase) via Nrf2 pathway | Cell culture / gene array data | Positive | Low |
| Epithalon activates telomerase (hTERT) in cultured human cells | In-vitro + small human pilot trials (Khavinson group) | Positive | Low |
| Epithalon extends lifespan or improves biomarkers in aged humans | Small uncontrolled pilot studies, n typically under 50 | Directionally positive, not confirmed | Very Low |
| BPC-157 accelerates soft-tissue healing | Rodent RCTs; no peer-reviewed human RCT | Positive in animals | Low |
| BPC-157 is safe in humans at research doses | No formal human pharmacokinetic study published | Unknown | Very Low |
| Subcutaneous route produces meaningful systemic exposure | Mechanism + pharmacokinetic analogy; no published glow-blend PK study | Assumed positive vs. oral | Moderate |
| The glow blend combination is superior to any single component | No combination study exists | Unstudied | Very Low |
Glow Peptide Dosage Chart
This chart reflects dose ranges appearing in the peer-reviewed and pre-clinical literature for each individual component. These are not FormBlends prescribing guidelines. A licensed clinician must determine appropriate dosing.
| Peptide | Starting Dose | Typical Dose Range | Frequency | Route | Cycle Length |
|---|---|---|---|---|---|
| GHK-Cu | 0.5 mg | 0.5 to 2 mg per session | Daily to 3x/week | Subcutaneous | 4 to 12 weeks |
| Epithalon | 5 mg/day | 5 to 10 mg/day | Daily x 10 to 20 days | Subcutaneous or IV (clinical) | 10 to 20-day course, 1 to 2x/year |
| BPC-157 | 250 mcg | 250 to 500 mcg per injection | Once or twice daily | Subcutaneous | 4 to 8 weeks |
| TB-500 (if included) | 2 mg/week | 2 to 5 mg/week loading; 1 to 2 mg/week maintenance | Weekly | Subcutaneous | Loading 4 to 6 weeks; maintenance ongoing |
How Does the Glow Blend Work, With Numbers?
GHK-Cu
GHK-Cu (molecular weight 340.38 Da as the free tripeptide) has a high affinity for copper(II) ions (association constant log K approximately 16, as reported in Pickart & Margolina, 2018, Biomolecules). This copper-chelating capacity is central to its proposed biological activity. In a 2012 gene microarray analysis (Pickart et al., published in JACS data supplements), GHK-Cu exposure modulated over 4,000 human genes, broadly in the direction of collagen I, III, and IV upregulation and MMP downregulation. The key caveat: gene modulation in cultured fibroblasts does not confirm the same effect size in intact skin at any given dose.
Epithalon
Epithalon (Ala-Glu-Asp-Gly, MW 390.35 Da) is proposed to upregulate hTERT (human telomerase reverse transcriptase) expression. Khavinson and colleagues reported increased telomerase activity in cultured human fetal fibroblasts and somatic cells in several papers published between 2003 and 2010 in the Bulletin of Experimental Biology and Medicine. Sample sizes in the human pilot studies were small (under 50 subjects in the best-documented trials) and lacked blinded controls, so the clinical magnitude of effect is not quantifiable from current data.
BPC-157
BPC-157's proposed mechanism centers on upregulation of VEGF (vascular endothelial growth factor) and EGF receptor pathways, promoting angiogenesis and fibroblast migration. Sikiric and colleagues at the University of Zagreb have published extensively in rodent models showing accelerated tendon and muscle healing; their most-cited work uses intraperitoneal or subcutaneous doses in the range of 10 mcg/kg. What this mechanism does NOT prove: the same receptor-level effect at human subcutaneous doses, or oral bioavailability sufficient to produce systemic effects.
What Most Glow Peptide Dosage Pages Get Wrong
This is the section competitors skip. It is also the most clinically important.
1. Oral bioavailability is functionally zero for most of these peptides
GHK is a tripeptide. In the GI tract, peptidases (particularly brush-border aminopeptidases and endopeptidases in the small intestine) cleave peptide bonds at rates that leave vanishingly small intact fractions for absorption. The same applies to Epithalon (4 amino acids) and BPC-157 (15 amino acids). BPC-157 is described as "stable in human gastric juice" by Sikiric's group, and some oral rodent experiments do show effects, but the fraction reaching systemic circulation intact has not been formally quantified in a human PK study. Anyone selling oral glow peptide capsules and claiming the same dose chart applies as for injectable forms is presenting unvalidated equivalence.
2. Blend stability is not the same as individual peptide stability
GHK-Cu and BPC-157 in the same vial introduce a potential copper-catalyzed oxidation concern. Copper ions in the presence of oxygen and reducing amino acid residues (particularly methionine or cysteine-containing peptides) can generate reactive oxygen species that degrade co-formulated peptides. BPC-157 does not contain cysteine or methionine, limiting but not eliminating this concern. No published stability data for this specific combination exists. The conservative approach: store reconstituted blends at 2 to 8 degrees Celsius, use within 28 days, and protect from light.
3. The "5 mg vial" label does not tell you the purity-adjusted dose
A vial labeled "5 mg BPC-157" at 90% HPLC purity delivers approximately 4.5 mg of the target peptide and 0.5 mg of unknown impurities. At 98% purity it delivers 4.9 mg. This matters when following a precise microgram-level protocol. Always check the purity percentage on the COA and adjust if purity falls below 97%.
4. "GHK-Cu" topical and injectable are not the same dose context
Cosmetic topical GHK-Cu products list concentrations of 1% to 5% by label, but transdermal penetration for a 340 Da charged peptide across intact stratum corneum is poor. Studies consistently show very low penetration fractions for intact skin without chemical enhancers or microneedling. The injectable dose of 0.5 to 2 mg delivers the peptide systemically or subdermally in a way a topical cream at any percentage does not replicate.
Reconstitution and Injection Math
Step-by-step reconstitution
- Wipe the vial stopper and the bacteriostatic water vial with an alcohol swab. Allow to air dry.
- Draw the target volume of bacteriostatic water into a 1 mL syringe.
- Insert the needle at an angle and let the water run slowly down the inside wall of the vial. Do not inject the stream directly onto the lyophilized powder.
- Do not shake. Swirl gently until dissolved. Lyophilized peptides typically dissolve within 30 to 90 seconds.
- Label the vial with the peptide name, concentration, and reconstitution date.
- Refrigerate at 2 to 8 degrees Celsius. Protect from light.
Concentration and draw-up table
| Vial Size | Bac Water Added | Concentration | 0.1 mL on Insulin Syringe = |
|---|---|---|---|
| 5 mg | 1.0 mL | 5 mg/mL | 0.5 mg |
| 5 mg | 2.5 mL | 2 mg/mL | 0.2 mg |
| 5 mg | 5.0 mL | 1 mg/mL | 0.1 mg |
| 10 mg | 2.5 mL | 4 mg/mL | 0.4 mg |
| 10 mg | 5.0 mL | 2 mg/mL | 0.2 mg |
For doses in micrograms: 250 mcg = 0.25 mg. At a 2 mg/mL concentration, 250 mcg = 0.125 mL = 12.5 units on a 100-unit insulin syringe.
Honest Head-to-Head: Glow Protocol vs. Alternatives
| Intervention | Evidence Base | Skin Quality Data | Safety Profile | Cost/Cycle | Glow Protocol Wins | Glow Protocol Loses |
|---|---|---|---|---|---|---|
| Glow Protocol (GHK-Cu + Epithalon + BPC-157) | Low to Moderate (individual components) | Indirect; no blend RCT | Limited human data | Moderate to high | Multi-pathway mechanistic rationale | No combination RCT; regulatory gray zone |
| Tretinoin (0.025 to 0.1%) | High; multiple RCTs | Strong; wrinkle and texture improvement confirmed in randomized trials | Well-characterized; dryness and irritation common initially | Low | Decades of RCT evidence; FDA approved | Glow protocol loses on evidence quality |
| Topical GHK-Cu alone (cosmetic) | Low; limited penetration data | Small studies with positive signals; confounded by vehicle effects | Generally safe; copper toxicity not reported at cosmetic concentrations | Low to moderate | Non-invasive; no injection risk | Bioavailability almost certainly lower than injectable |
| Collagen peptide supplements (oral, 5 to 10 g/day) | Moderate; multiple small RCTs for skin elasticity | Modest but statistically significant improvements in elasticity reported in several RCTs | Excellent; no significant adverse events | Low | Proven oral route for short-chain collagen fragments; simpler | Glow protocol loses on safety evidence simplicity |
| Hyaluronic acid fillers | High; large clinical series | Immediate volumizing effect; not collagen synthesis | Known AE profile; rare vascular occlusion | High | Immediate visible result | Different mechanism; not regenerative |
The glow protocol's honest competitive position: it offers a mechanistically interesting multi-target approach with a better injectable bioavailability argument than topical alternatives, but it concedes to tretinoin and oral collagen peptides on evidence quality, and it concedes to all approved options on regulatory standing.
How to Read a Glow Peptide COA
Do not accept a product without a third-party COA. Here is what each section should contain:
| COA Section | What to Look For | Red Flags |
|---|---|---|
| HPLC Purity | Above 98% by area | Below 95%; no chromatogram provided |
| Mass Spectrometry (MS) | Observed MW matches theoretical MW within 1 Da or confirmed by MS/MS fragmentation | COA lists only HPLC, no MS; wrong molecular weight range |
| Amino Acid Analysis | Correct composition and ratio matching the claimed sequence | Missing or not performed |
| Endotoxin Testing | Below 1 EU/mg for injectable use (USP standard) | Not tested; endotoxin above limit |
| Microbial Testing | Absence of specified organisms per USP or EP | Not tested; batch results missing |
| Heavy Metals | Lead, arsenic, cadmium below USP limits | Not tested |
| Residual Solvents | Within ICH Q3C limits | Not tested; synthesis route uses high-risk Class 1 solvents |
| Lot Number and Date | Traceable lot; dated within reasonable shelf life | Generic COA not lot-specific; no date |
Cycle Length, Timing, and Why It Matters
Each peptide in the blend has a different proposed mechanism and theoretical reason for cycle structure:
- GHK-Cu: Collagen remodeling is a slow process; 8 to 12 week cycles are most commonly used in aesthetic protocols to allow extracellular matrix changes to manifest. No tachyphylaxis mechanism is known at the receptor level, but sustained copper exposure above physiologic levels is theoretically undesirable.
- Epithalon: The Khavinson group's pilot protocols used 10 to 20 consecutive daily injections, one to two times per year. This intermittent structure was empirical, not derived from PK modeling. There is no validated washout requirement based on published data.
- BPC-157: Animal healing models show effects within days to weeks. Longer cycles of 4 to 8 weeks are used clinically for musculoskeletal applications. Whether continuous dosing produces receptor downregulation or tolerance is unknown.
A common combined glow protocol structure is: 20 daily injections (aligning with Epithalon's documented regimen), a 6 to 8 week washout, then reassessment. GHK-Cu and BPC-157 can be extended beyond 20 days at clinician discretion, as their cycle structures are not constrained by the same convention.
FAQ
What is the standard glow peptide dosage?
The glow protocol typically combines GHK-Cu, Epithalon, and BPC-157 at doses ranging from 0.5 mg to 2 mg per peptide per injection, titrated to the specific compound and user weight. Exact doses depend on the blend formulation and the supervising clinician's protocol.
How often should the glow protocol peptide be dosed?
Most glow protocol schedules run 5 days on, 2 days off, or daily for a defined cycle of 4 to 12 weeks, followed by a washout period. Specific frequency depends on which peptides are in the blend and the clinical endpoint being targeted.
What does a glow peptide dosage chart show?
A glow peptide dosage chart maps each peptide in the blend to its starting dose, titration steps, injection volume after reconstitution, cycle length, and any weight-based adjustments. The chart in this guide covers GHK-Cu, Epithalon, and BPC-157.
How do I reconstitute the glow blend peptide?
Add bacteriostatic water slowly down the vial wall. Do not shake. For a 5 mg vial with 2.5 mL bac water, each 0.1 mL drawn on an insulin syringe delivers 0.2 mg. Adjust the water volume to hit your target concentration.
Is the glow peptide protocol backed by clinical trials?
Individual peptides in the glow protocol have human pilot data (Epithalon) or animal and in-vitro data (GHK-Cu, BPC-157). No RCT has tested the specific glow blend combination. Evidence is Low to Moderate depending on the peptide.
Can I take the glow protocol peptides orally?
Oral bioavailability for these peptides is low to negligible. GI proteases cleave most peptide bonds before systemic absorption. Subcutaneous injection is the standard route used in research protocols.
What is the difference between the glow protocol and a standard GHK-Cu protocol?
A standalone GHK-Cu protocol targets collagen synthesis and antioxidant signaling. The glow protocol stacks GHK-Cu with telomere-associated peptides (Epithalon) and tissue-repair peptides (BPC-157) for broader skin, recovery, and longevity endpoints.
How do I know if my glow peptide has degraded?
Signs of degradation include visible cloudiness or particulate matter after reconstitution, a yellow or brown discoloration, or absence of expected effects at established doses. Degraded product should be discarded.
What should I look for on a glow peptide certificate of analysis?
Look for HPLC purity above 98%, mass spectrometry confirmation of molecular weight, absence of heavy metals, and microbial and endotoxin testing results. A COA without MS confirmation does not verify amino acid sequence.
Are there risks specific to the glow blend at higher doses?
GHK-Cu at supratherapeutic doses may cause nausea or injection site irritation. Epithalon has limited long-term safety data in humans. BPC-157 animal data is reassuring at standard doses, but human safety data remains sparse.
Where should I inject the glow protocol peptides?
Subcutaneous injection into the abdomen, lateral thigh, or flank is most common. Rotate sites to minimize lipodystrophy. Use a 27 to 31 gauge, 0.5 inch needle for subcutaneous delivery.
How long before I see results on the glow peptide protocol?
Based on the underlying research for individual components, skin-quality changes are reported after 4 to 8 weeks and recovery-related effects within 2 to 4 weeks. These timelines are extrapolated from component-level data, not glow-blend RCTs.
Sources
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. PMC6073405.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-2.
- Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epithalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-32.
- Sikiric P, Hahm KB, Bhatt DL, et al. Cytoprotection and injury control - pentadecapeptide BPC 157. Current Pharmaceutical Design. 2018;24(18):1994-2001.
- United States Pharmacopeia. General Chapter 85: Bacterial Endotoxins Test. USP-NF. Current edition.
- ICH Harmonised Tripartite Guideline Q3C(R6): Impurities: Guideline for Residual Solvents. 2016.
- Proksch E, Schunck M, Zague V, et al. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacology and Physiology. 2014;27(3):113-119.
- Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB Journal. 1996;10(9):1002-13.
Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before beginning any peptide protocol.
Research Compound: The peptides described on this page are research compounds or compounded medications. They are not FDA-approved drugs for the indications discussed. Their sale for human use may be subject to regulatory restrictions that vary by jurisdiction. FormBlends does not sell or supply peptides.
Results: Individual outcomes vary. The evidence grades in this article reflect the current state of published literature. Positive signals in animal or in-vitro studies do not guarantee equivalent effects in humans at the doses described.
Trademarks: "Glow Protocol" and related terms may be trademarks of their respective compounding or commercial entities. Use of these terms on this page is descriptive